A b s t r a c t
Class I HLA "blanks," defined traditionally by serologic assays in the clinical laboratory, might be due to the following: (1) homozygosity of the purported allele, (2) failure of antisera to recognize the allele, (3) low expression of the allele making it undetectable by the antisera, (4) an altered protein (single to multiple amino acid changes) with different epitopes, or (5) a lack or absence of cell surface antigen (ie, protein) present.
Alleles encoding molecules expressed weakly at the cell surface that might be detectable by flow cytometry but not by the basic lymphocyte microcytotoxicity test are identified as low expression. Low-expressing or nonexpressing alleles are designated null alleles, or a gene without a phenotype.
The introduction of molecular technology during the last decade into the clinical HLA laboratory has highlighted a potential 20% to 25% error rate when comparing DNA-based typing results with serologic data. [1] [2] [3] As a result of direct sequencing of such null alleles, the lack of detectable protein has been explained to be the result of nonsense, frame-shift, dysfunctional promoter sequence or splicing defect mutations. 4, 5 Thirty-five HLA class I (19 HLA-A, 15 HLA-B, and 1 HLA-C) and 7 HLA class II (3 DRB4, 2 DRB5, and 2 DPB1) null alleles have been described to date. 6 With the evolution of DNA typing technology, detected HLA diversity has increased dramatically, with now more than 1,000 class I and II alleles described at the sequence level. 7 Some of these new variants are nonexpressed or null alleles owing to mutations in their exons, introns, or promoter sequences. 8 Such null alleles might be mistyped or misinterpreted as expressed antigens when analyzed by low-resolution polymerase chain reaction (PCR)-based technology. On the other hand, serologic HLA typing alone will miss antigens that are expressed at a very low level or as a truncated product, with potentially severe consequences in clinical transplantation in either situation. 9 With current technologies, we have the capability to determine whether a null or low-expression allele has any antigenic properties (ie, whether an altered protein is present). Although relatively rare, discrimination between low-expression and null HLA alleles is of significant importance in the transplantation of hematopoietic progenitor stem cells. If a donor carries a null allele and the recipient an expressed allele, then the transplanted immune system of the donor will be able to mount an immune response against the recipient's tissues and organs, resulting in graft-vs-host disease. 10 Our purpose is to report a new HLA class I allele and define it as a null variant (nv), with its pedigree, DNA molecular typing, and DNA sequence.
Materials and Methods

Specimen Processing and Serologic HLA Typing
Specimens were collected in sodium heparin and acid citrate dextrose-A anticoagulants. Lymphocytes then were isolated from the sodium heparin specimens by using a standard density-gradient technique, 11 and the DNA was purified from the acid citrate dextrose-A specimens by means of a spin-column technique (Gentra Systems, Minneapolis, MN). All individuals were typed for HLA-A-, HLA-B-, HLA-DRB1-, and HLA-DQB1-encoded antigens. Typing for class I and class II HLA antigens was performed via the basic lymphocyte microcytotoxicity test, 12 using T cells and B cells isolated with nylon wool and commercial HLA typing trays (One Lambda, Canoga Park, CA).
PCR-Based Molecular HLA Typing
Methods used to detect the amplified PCR product included PCR-sequence-specific priming, PCR-sequencespecific oligonucleotide probes (SSOPs), and PCR-sequencebased typing (SBT).
Genomic level HLA-DRB1 and HLA-DQB1 typing of all individuals was performed using a reverse SSOP hybridization assay (Biotest, Dreieich, Germany). 13 HLA-A and HLA-B typing of some family members (index and 2 siblings) also was performed using a reverse SSOP hybridization assay (Biotest).
Sequencing then was performed using the ABI BigDye terminator cycle sequencing kit (PE Applied Biosystems, Foster City, CA). PCR amplification of exons 1, 2, and 3 was performed using cloned Pfu DNA polymerase (Stratagene, La Jolla, CA); PCR amplification of exons 4 through 7 was performed using Taq DNA polymerase (Promega, Madison, WI).
Results
We report an apparently healthy family of 8 with nearly identical parental haplotypes (a and c) and 1 HLA "blank" observed in 2 generations during 25 years, with identification of a new HLA allele (ie, nv).
❚Figure 1❚ illustrates the HLA typing serologic examinations for the family accomplished first in 1976 and repeated in 2000, with the maternal haplotype "c" showing the blank both times at the HLA-A locus as Ax. The blank also was observed in 2 male offspring in both instances.
DNA molecular typing performed by SSOP in 2001 is shown in ❚Figure 2❚, with the A01 allele reflecting the blank demonstrated in the mother and also transmitted to 2 male offspring but not detected by serologic testing. The presence of this A01 allele also was confirmed by SSOP typing performed by Orchid Diagnostics, Stamford, CT.
High-resolution typing in ❚Figure 3❚ shows the family pedigree from the C.W. Bill Young Department of Defense Marrow Donor Program, Kensington, MD, in 2002. The maternal allele "c" reflects the null variant, A 0101nv for the first time. Again, this nv allele also is transmitted to 2 offspring, and the virtual haploidentity (ie, a and c) of the 2 parents is shown.
❚Table 1❚ is a summary of typing results from 1976 through 2002 for both parents and the 2 male offspring with the blank or new allele (also called nv).
The PCR product for SBT from all 7 HLA-A coding exons was sequenced in both directions in 2 members of the family (the mother, haplotype c and d, and 1 offspring, haplotype a and c) who demonstrated the novel HLA-A allele. The second HLA-A allele in the mother, "d," was identified as A*2402, while the second HLA-A allele in the offspring, "a," was found to be A*0101.
SBT of maternal DNA is shown in ❚Figure 4❚. ❚Table 2❚ and ❚Table 3❚ show the primers used to sequence the HLA-A gene. The only unexpected DNA variant detected was a single point mutation; the nucleotide change was 215G to C, a guanine to cytosine transversion at nucleotide 215, which results in the R48P missense mutation (amino acid substitution of proline for arginine at codon 48) as shown in Figure 4 . The 215G to C nucleotide was predicted to destroy a SacII restriction site and create a SgrAI restriction site, and the expected R48P genotype of other members of the family was confirmed using these 2 enzymes. 
Discussion
The HLA complex is a cluster of tightly linked genes extending over approximately 4 cM of DNA, a chromosomal location of approximately 7 × 10 6 base pairs located on the short arm of chromosome 6 and containing more than 200 genes that are grouped into regions I, II, and III. Region I consists of genes that code for the heavy chains of the classic transplantation molecules, HLA-A, HLA-B, and HLA-C. The light chain gene product associated with these molecules is β 2 -microglobulin, which is located on chromosome 15. In addition to these classic histocompatibility genes, region I also contains some nonclassic genes, HLA-E, HLA-F, HLA-G, and HLA-H. The actual role of these genes in transplantation is not fully understood. Region II consists of 3 different class II molecules, HLA-DR, HLA-DQ, and HLA-DP, coding for the α and β chains for each molecule. Finally, region III contains several structurally and functionally diverse molecules, including C4, C2, factor B, and tumor necrosis factor to name a few.
HLA class I and II genes are among the most polymorphic gene complexes known, consisting of more than 130 different gene products that can be detected by classic serologic assays. 14 However, the real diversity of gene products is highly underestimated by at least 2 to 3 times, as demonstrated through the use of molecular assays. These nonserologic technologies, SSOP, sequence-specific priming, and direct nucleotide sequencing, permit new variant HLA molecules to be discovered routinely. Within this family of genes, not all are expressed routinely, for example, genes DPA2*, DPB2*, and DRB2* are known pseudogenes that contain mutations that prevent gene activation or transcription, and they go undetected by routine serologic methods.
The term polymorphic comes from the Greek words poly, meaning many, and morph, meaning shape or structure. When used to describe the HLA system, it means "variation at a single genetic locus and its products." A sequence variant at a gene is known as an allele. There are more than 200 different alleles within the HLA class I and II loci. As a result, the chance that the HLA locus on both homologous chromosomes of an individual will code for the same allele (ie, be homozygous) is very low. Therefore, most individuals are heterozygous at these loci, and both alleles will be expressed on the cell surface, making expression codominant with both products capable of presenting antigens to T cells. 15 Typically, HLA complex genes are inherited as a haplotype, which refers to a set of closely linked genes. Because the HLA complex is so polymorphic, most people will be heterozygous for different HLA haplotypes. However, there is approximately a 25% chance that siblings will inherit the same parental haplotypes and, thus, will be able to provide a match for each other. When parents have haplotypes in common, there also is a 25% chance that their offspring will be homozygous (Figure 3) . The likelihood of an individual being homozygous is proportional to the frequency of the haplotype in the population.
While the discovery of another HLA-A or HLA-B-specific subtype hardly will alter current clinical testing or transplantation procedures, not all undiscovered alleles are as well characterized. As a result of molecular technologies and the implementation of DNA typing and comparison of results with serologic data, interest is building in the category of blanks. Currently, the easiest way to detect blanks or nulls is to compare serologic data with DNA typing results ( ❚Figure 4❚ HLA-A 0101nv. A G to C point mutation at nucleotide position 215 results in an arginine (CGG) to proline (CCG) substitution at codon 48 (R48P). A, adenine; Ala, alanine; Arg, arginine; C, cytosine; G, guanine; Glu, glutamic acid; Pro, proline; S, both a cytosine and a guanine; T, thymine; black, guanine; blue, cytosine; green, adenine; red, thymine.
transplantation is to compare the sequence of the null with its normal counterpart by seeing whether the null allele is capable of transcription, and, if messenger RNA is produced, whether it is stable and can be translated into an altered or truncated protein.
Another class of mutations is concerned with the correct transportation and location of the protein, in this case to the cell surface. Even if it is located correctly, the gene product might not function correctly (ie, might not be able to interact with other proteins, etc).
If any of these are possibilities, one would look for this altered protein on the surface of cells. It should be kept in mind, though, that its concentration might be so low that it might go undetected or the technologies being used might not detect the altered protein. In addition, the possibility exists that the altered protein might exist in a secreted form. The immunogenicity status of HLA null mutations also must be known or ascertained to anticipate their role in rejection, graft-vs-host disease, and tolerance of such mutations in transplantation.
Results of serologic and molecular DNA low-, intermediate-, and high-resolution HLA typing during a span of 25 years were compared in 2 generations of a family of 8. A single maternal allele originally identified in 1976 as a blank or "c" was transmitted to 2 male offspring (Figures 1-3 , Table 1 ).
With further typing by molecular methods (low-resolution SSOP), what originally was called a blank in 1976 was identified in 2000 as HLA-A01 by our laboratory (SUNY Upstate Medical University, Syracuse, NY; Figure  2 ) and confirmed by Orchid Diagnostics (Table 1) ; this blank was not recognized serologically and is what we had identified as HLA-Ax for an alternative gene expression (Figure 1) .
The results were an enigma and a source of consternation to one of us (J.B.H.), who used this family that he knew well as a case study in parentage testing instruction during the 1970s. Haplotype "c," with an apparent blank, was transmitted to 2 male offspring (Figure 1) . It would reflect a potential maternal exclusion when homozygous A9 was postulated as one of the explanations for the presence of the blank; another postulated exclusion would reflect an alternative allele expression not detectable by available serologic HLA typing at that time. It was only with subsequent HLA molecular DNA typing almost 25 years later that this was clarified by detection of the maternal HLA 0101 nv in haplotype "c," which also was transmitted to 2 male offspring.
In It is unknown whether the new allele lacks or loses some serologic epitopes present in A*01011 (A1) because of the amino acid substitution at residue 48 or whether the new allele is not expressed at all. Initially, the former hypothesis seemed more likely to be true. However, Trinh and colleagues 16 reported that arginine (R) at residues 35 and 48 and glutamine (Q) at residue 32 of the heavy chain of HLA class I molecules interact with aspartate (D) at position 54 of β 2 -microglobulin. The substitution of arginine by proline at residue 48 might abrogate the interaction between residues of the α-1 domain of the heavy chain with those of β 2 -microglobulin. Such a failure in assembly might modify the 3-dimensional structure of an expressed protein.
Further studies (in progress) are necessary to clarify whether there is a protein product present, whether there is a product that binds β 2 -microglobulin partially (there are interactions with residues located at the α-3 domain) with an abnormal conformation, or whether the new allele does not interact with β 2 -microglobulin at all. If the presence of a heavy chain product is determined in studies underway, that might suggest the presence of an abnormal (ie, defective or impaired) allele. Interestingly, 2 novel alleles described recently (B*0730, A*2435) have substitutions at codon 48. 16 The allele B*0730 also has proline at codon 48. There is no report yet about their serotype, and it has not been reported that these alleles have altered expression. Usually, new alleles are reported without expression tests having been performed. Studies underway should clarify the molecular detail and structural and functional effects of this mutation.
We, therefore, conclude that mutations not only contribute to the polymorphism of HLA genes, but also might be a challenge in HLA typing, especially in the presence of blanks. Serologic HLA typing might or might not demonstrate a protein present with an HLA substitution mutation, while molecular DNA-based typing of HLA null alleles might or might not identify alleles important in organ transplantation. SBT might be necessary to clarify discrepancies between HLA serologic and other molecular DNA-based typing and to identify novel alleles, such as our new HLA-A allele, referred to as HLA-A 0101nv.
Our new allele, HLA-A 0101nv, as a single point mutation involving a cytosine for guanine transversion mutation, results in the substitution of arginine by proline. This might result in the absence of heavy chain formation or a distorted HLA molecule in which the β globulin heavy chain fails to bridge with β 2 -microglobulin, resulting in the absence of surface protein expression at HLA-A1 receptors as serologic epitopes.
Laboratory HLA typing of organ transplant donors and recipients, especially with the increasing number of living donors, needs to embrace molecular DNA-based typing to identify substitution mutations for optimal matching, with SBT to be applied when necessary to resolve discrepancies.
Undoubtedly, the number of defined HLA substitution mutations will increase and contribute to the polymorphism of existing HLA genes; these must be recognized and integrated into histocompatibility and immunogenetics laboratories, as well as transplantation services, with an appropriate strategy as outlined, proceeding from serologic typing to molecular DNA typing to SBT for clarification of identity and confirmation of the mutation in HLA expression.
